English
Firefly Luciferase CD19/CD20 Double Knockout Raji Cell Line
Firefly Luciferase CD19/CD20 Double Knockout Raji Cell Line
Artikelnummer
BPS82625
Verpackungseinheit
2 vials
Hersteller
BPS Bioscience
Verfügbarkeit:
wird geladen...
Preis wird geladen...
Products from BPS Bioscience require a minimum order value above 400€
Application: Use as control in CAR-T or NK co-culture killing assaysIn vitro and in vivo Bioluminescence Imaging
Background: The Raji cell line was established from a Burkitt's lymphoma patient. Raji cells constitutively express B cell antigens CD19, CD20, and CD22, and offer a physiologically relevant platform to evaluate cancer-directed immunotherapies such as Chimeric Antigen Receptor (CAR) T or CAR NK cells.CD19 (also known as Cluster of Differentiation 19, B-lymphocyte surface antigen B4, or CVID3) is a glycoprotein expressed on the surface of B lymphocytes through most phases of B cell maturation. It is strictly required for B cell terminal differentiation. Mutations in the CD19 gene cause severe immune-deficiency syndromes associated with impaired antibody production, such as CVID3 (common variable immuno-deficiency 3). The majority of B cell malignancies express normal to high levels of CD19, making it a nearly ideal target for cancer immunotherapy. Blinatumomab, a CD19/CD3 bi-specific T cell engager (BiTE) has been approved for relapsed/refractory B precursor ALL (Acute lymphoblastic leukemia) and CD19 was the target of the first approved CAR-T cell therapy. Studies of CD19 function and expression profiles will continue to broaden our knowledge and support broader applications in cancer therapy. CD20 (also known as B-lymphocyte antigen CD20, or MS4A1) is a non-glycosylated protein expressed on the surface of B-cells during all stages of B-cell development following the pre-B phase. The function and natural ligand of CD20 is not entirely clear. However, CD20 is a marker for several B-cell malignancies, including B-cell lymphomas, B-cell chronic lymphocytic leukemia, and melanoma cancer stem cells. Accordingly, several anti-CD20 monoclonal antibodies have been developed to effectively deplete B-cell populations and manage B-cell malignancies, as well as some inflammatory and autoimmune diseases. The first anti-CD20 monoclonal antibody was Rituximab, which was approved by the FDA in 1997. More recently, anti-CD20-CD19 bispecific CAR-T cells have been developed to address concerns over potential relapse in cancer patients.Firefly luciferase has been used as a sensitive reporter to study a wide range of biological responses. The signal generated by the firefly luciferase reporter is proportional to Raji cell numbers and facilitates the quantification of Raji cells killing upon co-culture with CAR-T or NK cells.
Description: Firefly Luciferase CD19/CD20 Double Knockout Raji Cell Line is a Raji cell line in which CD19 (Cluster of Differentiation 19, B lymphocyte surface antigen B4, or CVID3) and CD20 (B-lymphocyte antigen CD20, or MS4A1) have been genetically removed from Raji cells using CRISPR/Cas9 genome editing, while also constitutively expressing firefly (Photinus pyralis) luciferase under the control of a CMV promoter. This cell line was generated by using Firefly Luciferase Lentivirus (BPS Bioscience #79692) on CD19/CD20 Double Knockout Raji Cell Line (BPS Bioscience #82623).This cell line has been validated by genome sequencing, flow cytometry and luciferase activity measurement.
Host Cell Line: Raji human B lymphoblastoid cell line, derived from a patient with Burkitt lymphoma. Suspension cells.
Mycoplasma Testing: The cell line has been screened to confirm the absence of Mycoplasma species.
Storage Stability: Cells are shipped in dry ice and should immediately be thawed or stored in liquid nitrogen upon receipt. Do not use a -80°C freezer for long term storage. Contact technical support at support@bpsbioscience.com if the cells are not frozen in dry ice upon arrival.
Supplied As: Each vial contains ˃1 x 106 cells in 1 ml of Cell Freezing Medium (BPS Bioscience #79796)
Uniprot: CD19: P15391; CD20: P11836
Warnings: Avoid freeze/thaw cycles
Biosafety Level: BSL-2
Application: Use as control in CAR-T or NK co-culture killing assaysIn vitro and in vivo Bioluminescence Imaging
Background: The Raji cell line was established from a Burkitt's lymphoma patient. Raji cells constitutively express B cell antigens CD19, CD20, and CD22, and offer a physiologically relevant platform to evaluate cancer-directed immunotherapies such as Chimeric Antigen Receptor (CAR) T or CAR NK cells.CD19 (also known as Cluster of Differentiation 19, B-lymphocyte surface antigen B4, or CVID3) is a glycoprotein expressed on the surface of B lymphocytes through most phases of B cell maturation. It is strictly required for B cell terminal differentiation. Mutations in the CD19 gene cause severe immune-deficiency syndromes associated with impaired antibody production, such as CVID3 (common variable immuno-deficiency 3). The majority of B cell malignancies express normal to high levels of CD19, making it a nearly ideal target for cancer immunotherapy. Blinatumomab, a CD19/CD3 bi-specific T cell engager (BiTE) has been approved for relapsed/refractory B precursor ALL (Acute lymphoblastic leukemia) and CD19 was the target of the first approved CAR-T cell therapy. Studies of CD19 function and expression profiles will continue to broaden our knowledge and support broader applications in cancer therapy. CD20 (also known as B-lymphocyte antigen CD20, or MS4A1) is a non-glycosylated protein expressed on the surface of B-cells during all stages of B-cell development following the pre-B phase. The function and natural ligand of CD20 is not entirely clear. However, CD20 is a marker for several B-cell malignancies, including B-cell lymphomas, B-cell chronic lymphocytic leukemia, and melanoma cancer stem cells. Accordingly, several anti-CD20 monoclonal antibodies have been developed to effectively deplete B-cell populations and manage B-cell malignancies, as well as some inflammatory and autoimmune diseases. The first anti-CD20 monoclonal antibody was Rituximab, which was approved by the FDA in 1997. More recently, anti-CD20-CD19 bispecific CAR-T cells have been developed to address concerns over potential relapse in cancer patients.Firefly luciferase has been used as a sensitive reporter to study a wide range of biological responses. The signal generated by the firefly luciferase reporter is proportional to Raji cell numbers and facilitates the quantification of Raji cells killing upon co-culture with CAR-T or NK cells.
Description: Firefly Luciferase CD19/CD20 Double Knockout Raji Cell Line is a Raji cell line in which CD19 (Cluster of Differentiation 19, B lymphocyte surface antigen B4, or CVID3) and CD20 (B-lymphocyte antigen CD20, or MS4A1) have been genetically removed from Raji cells using CRISPR/Cas9 genome editing, while also constitutively expressing firefly (Photinus pyralis) luciferase under the control of a CMV promoter. This cell line was generated by using Firefly Luciferase Lentivirus (BPS Bioscience #79692) on CD19/CD20 Double Knockout Raji Cell Line (BPS Bioscience #82623).This cell line has been validated by genome sequencing, flow cytometry and luciferase activity measurement.
Host Cell Line: Raji human B lymphoblastoid cell line, derived from a patient with Burkitt lymphoma. Suspension cells.
Mycoplasma Testing: The cell line has been screened to confirm the absence of Mycoplasma species.
Storage Stability: Cells are shipped in dry ice and should immediately be thawed or stored in liquid nitrogen upon receipt. Do not use a -80°C freezer for long term storage. Contact technical support at support@bpsbioscience.com if the cells are not frozen in dry ice upon arrival.
Supplied As: Each vial contains ˃1 x 106 cells in 1 ml of Cell Freezing Medium (BPS Bioscience #79796)
Uniprot: CD19: P15391; CD20: P11836
Warnings: Avoid freeze/thaw cycles
Biosafety Level: BSL-2
| Artikelnummer | BPS82625 |
|---|---|
| Hersteller | BPS Bioscience |
| Hersteller Artikelnummer | 82625 |
| Verpackungseinheit | 2 vials |
| Mengeneinheit | PAK |
| Wirt | Human |
| Produktinformation (PDF) | Download |
| MSDS (PDF) |
|
Verwandte Artikel
Markieren Sie die Artikel, um Sie dem Warenkorb hinzuzufügen oder
Immer für Sie da
Gernot Ensinger, M.Sc.
Laurent Haze
